Global Adult Preventable Vaccines Market Growth 2026-2032
Description
The global Adult Preventable Vaccines market size is predicted to grow from US$ 22140 million in 2025 to US$ 31550 million in 2032; it is expected to grow at a CAGR of 5.3% from 2026 to 2032.
Adult preventable vaccines are immunizations designed to protect adults from common or high-risk infectious diseases. These vaccines aim to prevent the onset and spread of illnesses such as influenza, pneumonia, shingles, hepatitis B, and COVID-19 by boosting immunity in adults. They are particularly crucial for older individuals, those with chronic conditions, and immunocompromised populations. Adult vaccination is a vital public health strategy for maintaining individual health and controlling disease transmission within communities.
United States market for Adult Preventable Vaccines is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
China market for Adult Preventable Vaccines is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Europe market for Adult Preventable Vaccines is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Global key Adult Preventable Vaccines players cover Pfizer Inc., Merck & Co., Inc., GlaxoSmithKline plc (GSK), Sanofi Pasteur, Moderna, Inc., etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.
LP Information, Inc. (LPI) ' newest research report, the “Adult Preventable Vaccines Industry Forecast” looks at past sales and reviews total world Adult Preventable Vaccines sales in 2025, providing a comprehensive analysis by region and market sector of projected Adult Preventable Vaccines sales for 2026 through 2032. With Adult Preventable Vaccines sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Adult Preventable Vaccines industry.
This Insight Report provides a comprehensive analysis of the global Adult Preventable Vaccines landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Adult Preventable Vaccines portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Adult Preventable Vaccines market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Adult Preventable Vaccines and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Adult Preventable Vaccines.
This report presents a comprehensive overview, market shares, and growth opportunities of Adult Preventable Vaccines market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Inactivated Vaccines
Subunit Vaccines
Mrna Vaccines
Viral Vector Vaccines
Peptide Vaccines
Segmentation by Application:
Prevent Influenza
Prevent Pneumococcal Infection
Prevent Hepatitis B
Prevent Herpes Zoster
Prevent Human Papillomavirus (Hpv)
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Pfizer Inc.
Merck & Co., Inc.
GlaxoSmithKline plc (GSK)
Sanofi Pasteur
Moderna, Inc.
Serum Institute of India Pvt.
Bharat Biotech International
CSL Limited (Seqirus)
Emergent BioSolutions Inc.
Daiichi Sankyo Company
Novavax, Inc.
Sinovac Biotech
Sinopharm Group Co.,
Johnson & Johnson (Janssen)
AstraZeneca plc
Key Questions Addressed in this Report
What is the 10-year outlook for the global Adult Preventable Vaccines market?
What factors are driving Adult Preventable Vaccines market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Adult Preventable Vaccines market opportunities vary by end market size?
How does Adult Preventable Vaccines break out by Type, by Application?
Please note: The report will take approximately 2 business days to prepare and deliver.
Adult preventable vaccines are immunizations designed to protect adults from common or high-risk infectious diseases. These vaccines aim to prevent the onset and spread of illnesses such as influenza, pneumonia, shingles, hepatitis B, and COVID-19 by boosting immunity in adults. They are particularly crucial for older individuals, those with chronic conditions, and immunocompromised populations. Adult vaccination is a vital public health strategy for maintaining individual health and controlling disease transmission within communities.
United States market for Adult Preventable Vaccines is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
China market for Adult Preventable Vaccines is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Europe market for Adult Preventable Vaccines is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Global key Adult Preventable Vaccines players cover Pfizer Inc., Merck & Co., Inc., GlaxoSmithKline plc (GSK), Sanofi Pasteur, Moderna, Inc., etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.
LP Information, Inc. (LPI) ' newest research report, the “Adult Preventable Vaccines Industry Forecast” looks at past sales and reviews total world Adult Preventable Vaccines sales in 2025, providing a comprehensive analysis by region and market sector of projected Adult Preventable Vaccines sales for 2026 through 2032. With Adult Preventable Vaccines sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Adult Preventable Vaccines industry.
This Insight Report provides a comprehensive analysis of the global Adult Preventable Vaccines landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Adult Preventable Vaccines portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Adult Preventable Vaccines market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Adult Preventable Vaccines and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Adult Preventable Vaccines.
This report presents a comprehensive overview, market shares, and growth opportunities of Adult Preventable Vaccines market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Inactivated Vaccines
Subunit Vaccines
Mrna Vaccines
Viral Vector Vaccines
Peptide Vaccines
Segmentation by Application:
Prevent Influenza
Prevent Pneumococcal Infection
Prevent Hepatitis B
Prevent Herpes Zoster
Prevent Human Papillomavirus (Hpv)
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Pfizer Inc.
Merck & Co., Inc.
GlaxoSmithKline plc (GSK)
Sanofi Pasteur
Moderna, Inc.
Serum Institute of India Pvt.
Bharat Biotech International
CSL Limited (Seqirus)
Emergent BioSolutions Inc.
Daiichi Sankyo Company
Novavax, Inc.
Sinovac Biotech
Sinopharm Group Co.,
Johnson & Johnson (Janssen)
AstraZeneca plc
Key Questions Addressed in this Report
What is the 10-year outlook for the global Adult Preventable Vaccines market?
What factors are driving Adult Preventable Vaccines market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Adult Preventable Vaccines market opportunities vary by end market size?
How does Adult Preventable Vaccines break out by Type, by Application?
Please note: The report will take approximately 2 business days to prepare and deliver.
Table of Contents
113 Pages
- *This is a tentative TOC and the final deliverable is subject to change.*
- 1 Scope of the Report
- 2 Executive Summary
- 3 Global by Company
- 4 World Historic Review for Adult Preventable Vaccines by Geographic Region
- 5 Americas
- 6 APAC
- 7 Europe
- 8 Middle East & Africa
- 9 Market Drivers, Challenges and Trends
- 10 Manufacturing Cost Structure Analysis
- 11 Marketing, Distributors and Customer
- 12 World Forecast Review for Adult Preventable Vaccines by Geographic Region
- 13 Key Players Analysis
- 14 Research Findings and Conclusion
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
